- Home
- ADN vs CVKD Comparison
ADN vs CVKD Comparison
Compare ADN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- CVKD
- Stock Information
- Founded
- ADN 2006
- CVKD 2022
- Country
- ADN United States
- CVKD United States
- Employees
- ADN N/A
- CVKD N/A
- Industry
- ADN Power Generation
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- ADN Utilities
- CVKD Health Care
- Exchange
- ADN Nasdaq
- CVKD Nasdaq
- Market Cap
- ADN 8.5M
- CVKD 17.1M
- IPO Year
- ADN N/A
- CVKD 2023
- Fundamental
- Price
- ADN $1.82
- CVKD $15.24
- Analyst Decision
- ADN
- CVKD Strong Buy
- Analyst Count
- ADN 0
- CVKD 2
- Target Price
- ADN N/A
- CVKD $52.50
- AVG Volume (30 Days)
- ADN 28.4K
- CVKD 59.6K
- Earning Date
- ADN 10-15-2024
- CVKD 11-08-2024
- Dividend Yield
- ADN N/A
- CVKD N/A
- EPS Growth
- ADN N/A
- CVKD N/A
- EPS
- ADN N/A
- CVKD N/A
- Revenue
- ADN $7,026,000.00
- CVKD N/A
- Revenue This Year
- ADN $2,232.99
- CVKD N/A
- Revenue Next Year
- ADN $91.56
- CVKD N/A
- P/E Ratio
- ADN N/A
- CVKD N/A
- Revenue Growth
- ADN 9.01
- CVKD N/A
- 52 Week Low
- ADN $1.71
- CVKD $5.40
- 52 Week High
- ADN $18.90
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- ADN 41.18
- CVKD 60.90
- Support Level
- ADN $1.79
- CVKD $11.19
- Resistance Level
- ADN $2.17
- CVKD $15.93
- Average True Range (ATR)
- ADN 0.16
- CVKD 1.36
- MACD
- ADN 0.02
- CVKD 0.23
- Stochastic Oscillator
- ADN 23.91
- CVKD 61.01
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.